A Phase 4 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 72 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 10th largest by enrollment, is one of 6 that started in 2019, is one of 14 in phase 4, and was the 27th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 277 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 22nd largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2019, is one of 8 in phase 4, and was the 48th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to assess the impact of treatment with apremilast 30 mg twice daily for 16 weeks, compared to placebo, on health-related quality of life (QOL) in adults with manifestations of plaque psoriasis and impaired quality of life.
Participants will be randomized 2 (apremilast):1 (placebo) in approximately 10 countries in Western Europe. Participants will be block-randomized to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). Participants presenting with multiple manifestations will be allocated to the manifestation which is most severe, as determined by the participant. All manifestations will be assessed for efficacy at each study visit.
The study will consist of 4 phases:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Subject has presence of ≥ 1 clinical manifestations of plaque psoriasis, defined as at least one of the following:
Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories.
(NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions.)
Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
NOTE: Option 2 may not be acceptable as a highly effective contraception option in all countries per local guidelines/regulations.
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take apremilast 30 mg tablets orally twice a day for up to 52 weeks.
Drug: Apremilast
Participants will take placebo tablets orally twice a day for 16 weeks. After week 16, participants will be switched to receive apremilast 30 mg twice daily until Week 52.
Drug: Apremilast · Drug: Placebo
Apremilast 30 mg tablets taken orally twice a day.
Also known as: Otezla, CC-10004
Placebo tablets taken orally twice a day
Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.
Time frame: Baseline and week 16
Change From Baseline in DLQI at Week 16
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.
Time frame: Baseline and week 16
Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16
Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.
Time frame: Baseline and week 16
Change From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16
The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.
Time frame: Baseline and week 16
Change From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16
Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.
Time frame: Baseline and week 16
Percentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 16
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Time frame: Week 16
Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 16
The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (16 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).
Time frame: Week 16
Percent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 16
EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.
Time frame: Baseline and week 16
Percent Change From Baseline in EQ-5D Index Score at Week 16
EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.
Time frame: Baseline and week 16
Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 16
Change From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 16
Change From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 16
Change From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 16
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Placebo-controlled Period
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.
Time frame: From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period.
Number of Participants With Marked Laboratory Abnormalities During the Placebo-controlled Period
Marked laboratory abnormalities are defined for each parameter below. ULN = upper limit of normal
Time frame: 16 weeks
Change From Baseline in Blood Pressure During the Placebo-controlled Period
Time frame: Baseline, week 2, week 4, and week 16
Change From Baseline in Pulse Rate During the Placebo-controlled Period
Time frame: Baseline and week 2, week 4, and week 16
Change From Baseline in Body Weight During the Placebo-controlled Period
Time frame: Baseline and week 2, week 4, and week 16
Change From Baseline in Waist Circumference During the Placebo-controlled Period
Time frame: Baseline and week 2, week 4, and week 16
Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in DLQI at Weeks 32 and 52
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.
Time frame: Baseline, week 32 and week 52
Change From Baseline in DLQI at Weeks 32 and 52
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.
Time frame: Baseline, week 32 and week 52
Change From Baseline in Itch NRS Score at Weeks 32 and 52
The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.
Time frame: Baseline, week 32 and week 52
Change From Baseline in Skin Discomfort/Pain VAS at Weeks 32 and 52
Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.
Time frame: Baseline, week 32 and week 52
Percent Change From Baseline in BSA Affected by Psoriasis at Weeks 32 and 52
Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.
Time frame: Baseline, week 32 and week 52
Percentage of Participants Who Achieved a PBI Score of ≥ 1 at Weeks 32 and 52
The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (32 weeks and 52 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).
Time frame: Week 32 and week 52
Percentage of Participants Who Achieved a PASI Score < 3 at Weeks 32 and 52
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
Time frame: Week 32 and week 52
Percent Change From Baseline in EQ-5D VAS Score at Week 52
EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.
Time frame: Baseline and week 52
Percent Change From Baseline in EQ-5D Index Score at Week 52
EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.
Time frame: Baseline and week 52
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 52
Change From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 52
Change From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 52
Change From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
Time frame: Baseline and week 52
Number of Participants With TEAEs During Apremilast Treatment
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.
Time frame: From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.
Number of Participants With Marked Laboratory Abnormalities During Apremilast Treatment
Time frame: From first dose of apremilast up to 28 days after last dose; up to 40 weeks for participants initially randomized to placebo and 56 weeks for participants initially randomized to apremilast.
Change From Baseline in Blood Pressure at End of Apremilast Extension Period
Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Change From Baseline in Pulse Rate at End of Apremilast Extension Period
Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Change From Baseline in Body Weight at End of Apremilast Extension Period
Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Change From Baseline in Waist Circumference at End of Apremilast Extension Period
Time frame: Baseline (defined as the last value measured on or before the day of the first apremilast dose) and end of apremilast extension period; week 52, or earlier for participants who discontinued prior to week 52
Eligible participants were enrolled at 55 centers in France, Germany, Italy, Spain, Switzerland, and the United Kingdom. The study consisted of a 16-week placebo-controlled period and a 36-week apremilast extension period.
| Milestone | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Started | 92 | 185 |
| Received study drug | 91 | 185 |
| Completed | 69 | 152 |
| Not completed | 23 | 33 |
| Withdrew: Adverse event | 8 | 16 |
| Withdrew: Lack of efficacy | 2 | 4 |
| Withdrew: Withdrawal by subject | 12 | 10 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Reason unknown | 1 | 0 |
| Milestone | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Started | 69 | 152 |
| Completed | 53 | 105 |
| Not completed | 16 | 47 |
| Withdrew: Adverse event | 6 | 9 |
| Withdrew: Lack of efficacy | 2 | 11 |
| Withdrew: Withdrawal by subject | 7 | 20 |
| Withdrew: Non-compliance with study drug | 0 | 2 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 3 |
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.
| percentage of participants | Placebo | Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 | 41.3 (30.0 to 52.6) | 73.3 (66.7 to 79.9) |
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.
| score on a scale | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in DLQI at Week 16 | -3.4 ± 0.80 | -8.7 ± 0.54 |
Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.
| percent change | Placebo | Apremilast 30 mg |
|---|---|---|
| Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis at Week 16 | 18.5 ± 12.95 | -19.8 ± 6.58 |
The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.
| score on a scale | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Itch Numeric Rating Scale (NRS) Score at Week 16 | -0.9 ± 0.32 | -2.5 ± 0.21 |
Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.
| score on a scale | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Skin Discomfort/Pain Visual Analog Scale (VAS) at Week 16 | -5.4 ± 3.61 | -21.5 ± 2.36 |
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
| percentage of participants | Placebo | Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved a Psoriasis Area Severity Index (PASI) Score < 3 at Week 16 | 26.3 (16.6 to 36.0) | 39.7 (32.3 to 47.1) |
The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (16 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).
| percentage of participants | Placebo | Apremilast 30 mg |
|---|---|---|
| Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Global Score of ≥ 1 at Week 16 | 39.9 (28.8 to 51.0) | 76.6 (70.2 to 83.1) |
EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.
| percent change | Placebo | Apremilast 30 mg |
|---|---|---|
| Percent Change From Baseline in European Quality of Life 5-Dimension (EQ-5D) VAS Score at Week 16 | 18.9 ± 15.96 | 33.8 ± 10.67 |
EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.
| percent change | Placebo | Apremilast 30 mg |
|---|---|---|
| Percent Change From Baseline in EQ-5D Index Score at Week 16 | 165.9 ± 89.80 | 17.8 ± 59.59 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.
| percent impairment | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Psoriasis (WPAI: PSO) at Week 16: Percentage Work Time Missed | -4.1 ± 2.56 | -0.9 ± 1.54 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 16: Percentage Work Impairment | -11.5 ± 3.82 | -13.9 ± 2.32 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 16: Percentage Overall Work Impairment | -13.2 ± 4.35 | -13.8 ± 2.63 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 16: Percentage Activity Impairment | -13.4 ± 3.66 | -21.2 ± 2.24 |
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.
| Participants | Placebo | Apremilast 30 mg |
|---|---|---|
| Any TEAE | 54 | 152 |
| Drug-related TEAE | 26 | 113 |
| Severe TEAEs | 1 | 10 |
| Serious TEAEs | 0 | 8 |
| Serious drug-related TEAE | 0 | 1 |
| TEAE leading to drug interruption | 0 | 9 |
| TEAE leading to drug withdrawal | 8 | 18 |
| TEAE leading to death | 0 | 0 |
Marked laboratory abnormalities are defined for each parameter below. ULN = upper limit of normal
| Participants | Placebo | Apremilast 30 mg |
|---|---|---|
| Alanine Aminotransferase > 3 × ULN | 0 | 2 |
| Albumin < 25 g/L | 0 | 0 |
| Alkaline Phosphatase > 400 U/L | 0 | 0 |
| Aspartate Aminotransferase > 3 × ULN | 0 | 1 |
| Bilirubin (umol/L) > 1.8 × ULN | 0 | 0 |
| Blood Urea Nitrogen > 15 mmol/L | 0 | 2 |
| Calcium < 1.8 mmol/L | 0 | 0 |
| Calcium > 3.0 mmol/L | 0 | 0 |
| Cholesterol > 7.8 mmol/L | 0 | 1 |
| Creatinine > 1.7 × ULN | 0 | 1 |
| Glucose < 2.8 mmol/L | 0 | 0 |
| Glucose > 13.9 mmol/L | 0 | 3 |
| Hemoglobin A1C (Fasting) > 9% | 0 | 3 |
| Lactate Dehydrogenase > 3 × ULN | 0 | 0 |
| Potassium < 3.0 mmol/L | 0 | 0 |
| Potassium > 5.5 mmol/L | 0 | 1 |
| Sodium < 130 mmol/L | 0 | 0 |
| Sodium > 150 mmol/L | 0 | 0 |
| Triglycerides > 3.4 mmol/L | 6 | 6 |
| Hemoglobin: Female < 85 g/L, Male < 105 g/L | 0 | 0 |
| Hemoglobin: Female > 170 g/L, Male > 185 g/L | 0 | 0 |
| Leukocytes < 1.5 × 10^9/L | 0 | 0 |
| Lymphocytes < 0.8 × 10^9/L | 1 | 2 |
| Neutrophils, Segmented < 1.0 × 10^9/L | 0 | 0 |
| Platelets < 75 × 10^9/L | 0 | 1 |
| Platelets > 600 × 10^9/L | 0 | 0 |
| mmHg | Placebo | Apremilast 30 mg |
|---|---|---|
| Systolic: week 2 | -0.5 ± 11.17 | 0.1 ± 12.44 |
| Systolic: week 4 | 1.9 ± 12.29 | 0.4 ± 11.88 |
| Systolic: week 16 | 2.2 ± 13.77 | 1.0 ± 12.66 |
| Diastolic: week 2 | -0.1 ± 7.89 | -0.6 ± 8.27 |
| Diastolic: week 4 | 1.3 ± 7.62 | -1.0 ± 9.51 |
| Diastolic: week 16 | 0.8 ± 8.29 | 0.6 ± 9.12 |
| beats/minute | Placebo | Apremilast 30 mg |
|---|---|---|
| Week 2 | 0.3 ± 10.82 | 3.4 ± 9.75 |
| Week 4 | -0.4 ± 10.17 | 3.5 ± 10.43 |
| Week 16 | 1.0 ± 9.97 | 2.0 ± 10.99 |
| kg | Placebo | Apremilast 30 mg |
|---|---|---|
| Week 2 | -0.02 ± 1.161 | -0.31 ± 1.188 |
| Week 4 | 0.04 ± 1.285 | -0.57 ± 2.060 |
| Week 16 | 0.08 ± 2.337 | -0.98 ± 2.722 |
| cm | Placebo | Apremilast 30 mg |
|---|---|---|
| Week 2 | -0.2 ± 3.93 | 0.2 ± 3.49 |
| Week 4 | -0.1 ± 4.89 | -0.3 ± 3.63 |
| Week 16 | 0.1 ± 6.16 | -0.9 ± 5.06 |
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life (QOL). The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL.
| percentage of participants | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | 68.1 (55.8 to 78.8) | 68.4 (60.4 to 75.7) |
| Week 52 | 76.8 (65.1 to 86.1) | 79.6 (72.3 to 85.7) |
The DLQI is a 10-item skin disease-specific questionnaire used to evaluate the impact of skin disease on health-related quality of life. The items address symptoms and feelings, daily activities, leisure, work/school, personal relationships, and issues with treatment. Questions are answered on a 4-point scale from 0 (not at all/not applicable) to 3 (very much). Item scores are added to provide a total score from 0 to 30, with higher scores indicating greater impairment of QOL. A negative change from baseline indicates improvement in quality of life.
| score on a scale | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | -9.8 ± 8.19 | -9.9 ± 7.28 |
| Week 52 | -11.3 ± 7.84 | -11.2 ± 7.08 |
The Itch Numeric Rating Scale (NRS) asked participants to assess the worst severity of itch experienced over the past 24 hours on an 11-point scale anchored from 0, representing 'no itching' to 10, representing 'worst itch imaginable'. A negative change from baseline indicates improvement in itch severity.
| score on a scale | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | -3.2 ± 3.50 | -2.8 ± 3.22 |
| Week 52 | -3.9 ± 3.61 | -3.3 ± 3.19 |
Participants were asked to indicate their level of skin discomfort/pain in the past week by placing a vertical stroke on a 100 mm horizontal line on which the left-hand boundary (0) represents no skin discomfort/pain, and the right-hand boundary (100) represents worst possible skin discomfort/pain. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement in skin discomfort/pain.
| score on a scale | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | -28.4 ± 38.40 | -22.6 ± 33.71 |
| Week 52 | -35.0 ± 36.76 | -31.0 ± 34.77 |
Body surface area is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint"), which equates to approximately 1% of total BSA.
| percent change | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | -49.5 ± 47.35 | -40.2 ± 51.79 |
| Week 52 | -49.9 ± 53.25 | -32.0 ± 93.09 |
The PBI is a validated patient-reported instrument to assess patient-relevant benefits of psoriasis treatment. Prior to starting study treatment, participants were asked to assess the importance of a series of treatment goals (from not important to very important) by completing the Patient Needs Questionnaire (PNQ). After a period of treatment (32 weeks and 52 weeks), participants were then asked to assess the extent to which these goals were achieved (from not at all to very) by completing the Patient Benefit Questionnaire (PBQ). The Patient Benefit Index represents the benefits realized as a function of most important needs. The PBI score ranges from 0 (no benefit) to 4 (maximum benefit).
| percentage of participants | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | 66.7 (54.3 to 77.6) | 67.8 (59.7 to 75.1) |
| Week 52 | 65.2 (52.8 to 76.3) | 63.8 (55.6 to 71.4) |
The PASI score is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and the values for each anatomic region are summed to yield the PASI score. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.
| percentage of participants | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Week 32 | 58.0 (45.5 to 69.8) | 40.1 (32.3 to 48.4) |
| Week 52 | 50.7 (38.4 to 63.0) | 37.5 (29.8 to 45.7) |
EQ-5D measures the participant's general health state on a vertical VAS and five quality of life domains. The EQ-5D VAS score ranges from 0 to 100, where a score of 0 indicates the worst imaginable health states and a score of 100 indicates the best imaginable health state. A positive change from baseline indicates improvement.
| percent change | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Percent Change From Baseline in EQ-5D VAS Score at Week 52 | 51.4 ± 132.13 | 33.6 ± 78.53 |
EQ-5D measures the participants general health state as a vertical VAS and 5 quality of life domains: mobility, self-care, main activity (work, study, housework, family/leisure activities), pain/discomfort, and anxiety/depression. Each dimension is rated on three levels (no problems, some/moderate problems, extreme problems). An EQ-5D summary index is derived by applying a formula that attaches values (weights) to each of the levels in each dimension. EQ-5D index values were derived using the UK scoring algorithm, where a higher score indicates a better health state. The range of the score is from -0.224 to 1, with 0 corresponding to death, 1 corresponding to full health, and negative numbers indicate health states worse than death. A positive change from baseline indicates improvement.
| percent change | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Percent Change From Baseline in EQ-5D Index Score at Week 52 | 214.103 ± 1799.6328 | 11.039 ± 224.3001 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent of work time missed is derived from the number of hours of work missed due to psoriasis symptoms as a percentage of total hours that should have been worked. A higher percentage indicates more hours missed, and a negative change from baseline indicates improvement.
| percent impairment | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 52: Percentage Work Time Missed | -4.6 ± 17.43 | -3.2 ± 17.11 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent impairment while working was derived from the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 52: Percentage Work Impairment | -21.0 ± 29.82 | -24.4 ± 26.78 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent overall work impairment takes into account both hours missed due to psoriasis symptoms and the participant's assessment of the degree to which psoriasis affected their productivity while working. A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 52: Percentage Overall Work Impairment | -21.7 ± 30.12 | -25.3 ± 29.91 |
The WPAI: PSO is a self-administered questionnaire designed to address impairment to the work productivity and activity of participants due to psoriasis in the past 7 days. Percent activity impairment is derived from the patient's assessment of the degree to which psoriasis affected their regular daily unpaid activities, measured on a VAS from 1 (no effect on daily activities) to 10 (psoriasis completely prevented daily activities). A higher percentage indicates greater impairment and less productivity, and a negative change from baseline indicates improvement.
| percent impairment | Placebo / Apremilast 30 mg | Apremilast 30 mg |
|---|---|---|
| Change From Baseline in WPAI: PSO at Week 52: Percentage Activity Impairment | -32.7 ± 33.94 | -30.5 ± 27.01 |
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening of a preexisting condition was considered an AE. A serious adverse event (SAE) is any AE occurring at any dose that: * Resulted in death; * Was life-threatening; * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity; * Was a congenital anomaly/birth defect; * Constituted an important medical event. The Investigator assessed the severity/intensity of each event as mild, moderate, or severe based on level of symptoms.
| Participants | Apremilast 30 mg |
|---|---|
| Any TEAE | 217 |
| Drug-related TEAE | 152 |
| Severe TEAEs | 14 |
| Serious TEAEs | 18 |
| Serious drug-related TEAE | 2 |
| TEAE leading to drug interruption | 19 |
| TEAE leading to drug withdrawal | 31 |
| TEAE leading to death | 0 |
| Participants | Apremilast 30 mg |
|---|---|
| Alanine Aminotransferase > 3 × ULN | 2 |
| Albumin < 25 g/L | 0 |
| Alkaline Phosphatase > 400 U/L | 0 |
| Aspartate Aminotransferase > 3 × ULN | 1 |
| Bilirubin > 1.8 × ULN | 1 |
| Blood Urea Nitrogen > 15 mmol/L | 2 |
| Calcium < 1.8 mmol/L | 1 |
| Calcium > 3.0 mmol/L | 0 |
| Cholesterol > 7.8 mmol/L | 3 |
| Creatinine > 1.7 × ULN | 1 |
| Glucose < 2.8 mmol/L | 0 |
| Glucose > 13.9 mmol/L | 7 |
| Hemoglobin A1C (Fasting) > 9% | 3 |
| Lactate Dehydrogenase > 3 × ULN | 0 |
| Potassium < 3.0 mmol/L | 0 |
| Potassium > 5.5 mmol/L | 2 |
| Sodium < 130 mmol/L | 0 |
| Sodium > 150 mmol/L | 0 |
| Triglycerides > 3.4 mmol/L | 22 |
| Hemoglobin: Female < 85 g/L, Male < 105 g/L | 1 |
| Hemoglobin: Female > 170 g/L, Male > 185 g/L | 0 |
| Leukocytes < 1.5 × 10^9/L | 0 |
| Lymphocytes < 0.8 × 10^9/L | 3 |
| Neutrophils, Segmented < 1.0 × 10^9/L | 0 |
| Platelets < 75 × 10^9/L | 2 |
| Platelets > 600 × 10^9/L | 0 |
| mmHg | Apremilast 30 mg |
|---|---|
| Systolic | 0.1 ± 13.68 |
| Diastolic | 0.1 ± 8.98 |
| beats/minute | Apremilast 30 mg |
|---|---|
| Change From Baseline in Pulse Rate at End of Apremilast Extension Period | 1.0 ± 10.29 |
| kg | Apremilast 30 mg |
|---|---|
| Change From Baseline in Body Weight at End of Apremilast Extension Period | -1.20 ± 3.802 |
| cm | Apremilast 30 mg |
|---|---|
| Change From Baseline in Waist Circumference at End of Apremilast Extension Period | -0.8 ± 4.97 |
Collected over Placebo-controlled period: From first dose of study drug to week 16 or up to 28 days after last dose for participants who didn't enter the apremilast extension period. Apremilast extension period: From first dose of apremilast in the extension period to 28 days after last dose, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Period: Placebo | 0/92 (0%) | 0/92 (0%) | 38/92 (41.3%) |
| Placebo-controlled Period: Apremilast 30 mg | 0/185 (0%) | 8/185 (4.3%) | 113/185 (61.1%) |
| Apremilast Extension Period: Apremilast 30 mg | 0/221 (0%) | 12/221 (5.4%) | 93/221 (42.1%) |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast 30 mg | Apremilast Extension Period: Apremilast 30 mg |
|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/92 | 2/185 | 0/221 |
| Atrial fibrillationCardiac disorders | 0/92 | 1/185 | 0/221 |
| IridocyclitisEye disorders | 0/92 | 1/185 | 0/221 |
| Pancreatitis acuteGastrointestinal disorders | 0/92 | 1/185 | 0/221 |
| Cerebral infarctionNervous system disorders | 0/92 | 1/185 | 0/221 |
| SyncopeNervous system disorders | 0/92 | 1/185 | 0/221 |
| Renal colicRenal and urinary disorders | 0/92 | 1/185 | 0/221 |
| Peripheral ischaemiaVascular disorders | 0/92 | 1/185 | 0/221 |
| Abdominal painGastrointestinal disorders | 0/92 | 0/185 | 1/221 |
| FaecalomaGastrointestinal disorders | 0/92 | 0/185 | 1/221 |
| Event | Placebo-controlled Period: Placebo | Placebo-controlled Period: Apremilast 30 mg | Apremilast Extension Period: Apremilast 30 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/92 | 61/185 | 22/221 |
| NauseaGastrointestinal disorders | 5/92 | 37/185 | 10/221 |
| HeadacheNervous system disorders | 5/92 | 37/185 | 19/221 |
| NasopharyngitisInfections and infestations | 11/92 | 18/185 | 25/221 |
| PsoriasisSkin and subcutaneous tissue disorders | 10/92 | 5/185 | 20/221 |
| Abdominal pain upperGastrointestinal disorders | 4/92 | 12/185 | 3/221 |
| Back painMusculoskeletal and connective tissue disorders | 4/92 | 6/185 | 12/221 |
| Abdominal painGastrointestinal disorders | 1/92 | 10/185 | 4/221 |
All randomized participants
| Age, Continuous(years) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 50.9 ± 13.68 | 47.4 ± 14.28 | 48.6 ± 14.16 |
| Age, Customized(Participants) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| < 65 years | 73 | 158 | 231 |
| ≥ 65 years | 19 | 27 | 46 |
| Sex: Female, Male(Participants) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| Female | 35 | 79 | 114 |
| Male | 57 | 106 | 163 |
| Race/Ethnicity, Customized(Participants) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| White | 89 | 179 | 268 |
| Black or African American | 0 | 2 | 2 |
| Asian | 1 | 1 | 2 |
| Not Collected or Unknown | 2 | 3 | 5 |
| Region of Enrollment(Participants) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| France | 6 | 13 | 19 |
| Germany | 45 | 102 | 147 |
| Italy | 8 | 11 | 19 |
| Spain | 23 | 24 | 47 |
| Switzerland | 1 | 7 | 8 |
| United Kingdom | 9 | 28 | 37 |
| Duration of Plaque Psoriasis(years) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 18.41 ± 13.350 | 16.31 ± 13.116 | 17.01 ± 13.207 |
| Primary Manifestations for Stratifications(Participants) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| Scalp Psoriasis | 23 | 45 | 68 |
| Nail Psoriasis | 20 | 40 | 60 |
| Palmoplantar Psoriasis | 10 | 22 | 32 |
| Genital Psoriasis | 15 | 28 | 43 |
| Psoriasis in Visible Locations | 24 | 50 | 74 |
| Dermatology Life Quality Index (DLQI) Score(score on a scale) | Placebo / Apremilast 30 mg | Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 18.5 ± 4.94 | 18.1 ± 4.86 | 18.2 ± 4.88 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Mar 2019 to primary completion in Feb 2021, 22 months.
Results were first posted in Jan 2022, 11 months after primary completion.
Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.
Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast